Results 61 to 70 of about 15,308 (249)

Disruptores endocrinos y su camino hacia el desequilibrio metabólico

Revista Colombiana de Endocrinología, Diabetes y Metabolismo, 2020
El presente artículo de revisión tiene como objetivo presentar, de forma resumida, la evidencia que existe sobre las repercusiones metabólicas a nivel de obesidad y diabetes, que se genera como consecuencia de la exposición a sustancias químicas ...
P. Sánchez, M. Zanabria, S. Latorre, J. Calvache, A. Coy, W. Rojas   +5 more
doaj   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

Endocrine disruptors

International Journal of Noncommunicable Diseases, 2022
Bhanu Malhotra, Sanjay Kumar Bhadada
openaire   +2 more sources

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Correction to: Impact of perinatal environmental health education intervention on exposure to endocrine disruptors during pregnancy—PREVED study: study protocol for a randomized controlled trial

Trials, 2021
Houria E. L. Ouazzani, Steeve Rouillon, Nicolas Venisse, Lynda Sifer-Rivière, Antoine Dupuis, Guillaume Cambien, Sarah Ayraud-Thevenot, Anne-Sophie Gourgues, Pascale Pierre-Eugène, Fabrice Pierre, Sylvie Rabouan, DisProSE Group, Virginie Migeot, Marion Albouy-Llaty   +13 more
doaj   +1 more source

Cancer cell‐intrinsic type 1 interferon: production, signaling, and outcomes within sex‐biased, female malignancies

Molecular Oncology, EarlyView.
The cell‐autonomous roles of interferon type 1 vary based on duration and intensity. While acute, robust signaling results in cancer cell cytotoxic effects, sustained, low‐level signaling is associated with tumor‐promoting effects. This review summarizes current research of IFN‐1 in cancer and within the clinical setting, with an emphasis on female ...
Ashlyn Conant, Nora Badiner, Sharon Asariah, Kiera McGivney, Vishwa Shah, Tise Suzuki, Yevgeniya J. Ioffe, Juli J. Unternaehrer   +7 more
wiley   +1 more source

Estrogenic and androgenic activities in total plasma measured with reporter-gene bioassays: Relevant exposure measures for endocrine disruptors in epidemiologic studies?

Environment International, 2011
Measurements of estrogenic and androgenic activities in total plasma with Chemically Activated LUciferase gene eXpression (CALUX®) bioassays could provide biologically relevant measures for exposure to endocrine disruptors in epidemiologic studies.
Marijn M. Brouwers, Harrie Besselink, Reini W. Bretveld, Rob Anzion, Paul T.J. Scheepers, Abraham Brouwer, Nel Roeleveld   +6 more
doaj   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Endocrine Disruptors

Güncel Pediatri, 2008
Endocrine disruptors are of special interest because they mimic, block, or in some way alter the activity of endogenous chemicals that are synthesized by the endocrine system. Besides many other organs, they especially affect the urinary system and the thyroid glands.
openaire   +3 more sources